

# Lynne M Mofenson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3745262/publications.pdf>

Version: 2024-02-01

321  
papers

22,950  
citations

9264

74  
h-index

10445

139  
g-index

411  
all docs

411  
docs citations

411  
times ranked

12262  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. <i>BMJ, The</i> , 2020, 370, m3320.	6.0	1,474
2	Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. <i>Lancet, The</i> , 1999, 354, 795-802.	13.7	1,341
3	Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1â€“Infected Women and Prevention of Perinatal HIV-1 Transmission. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 29, 484-494.	2.1	763
4	Combination Antiretroviral Strategies for the Treatment of Pregnant HIV-1â€“Infected Women and Prevention of Perinatal HIV-1 Transmission. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 29, 484-494.	2.1	553
5	Viral Load and Disease Progression in Infants Infected with Human Immunodeficiency Virus Type 1. <i>New England Journal of Medicine</i> , 1997, 336, 1337-1342.	27.0	524
6	Risk Factors for Perinatal Transmission of Human Immunodeficiency Virus Type 1 in Women Treated with Zidovudine. <i>New England Journal of Medicine</i> , 1999, 341, 385-393.	27.0	517
7	Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. <i>Lancet, The</i> , 2003, 362, 859-868.	13.7	476
8	Obstetrical Factors and the Transmission of Human Immunodeficiency Virus Type 1 from Mother to Child. <i>New England Journal of Medicine</i> , 1996, 334, 1617-1623.	27.0	427
9	Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries. <i>Aids</i> , 2012, 26, 2039-2052.	2.2	382
10	Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). <i>Aids</i> , 2001, 15, 1951-1957.	2.2	368
11	Perinatal Transmission of Human Immunodeficiency Virus Type 1 by Pregnant Women with RNA Virus Loads <1000 Copies/mL. <i>Journal of Infectious Diseases</i> , 2001, 183, 539-545.	4.0	356
12	Antiretroviral Therapy during Pregnancy and the Risk of an Adverse Outcome. <i>New England Journal of Medicine</i> , 2002, 346, 1863-1870.	27.0	356
13	Extended Antiretroviral Prophylaxis to Reduce Breast-Milk HIV-1 Transmission. <i>New England Journal of Medicine</i> , 2008, 359, 119-129.	27.0	351
14	Two-Dose Intrapartum/Newborn Nevirapine and Standard Antiretroviral Therapy to Reduce Perinatal HIV Transmission<SUBTITLE>A Randomized Trial</SUBTITLE>. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 189.	7.4	317
15	Lack of Long-term Effects of In Utero Exposure to Zidovudine Among Uninfected Children Born to HIV-Infected Women. <i>JAMA - Journal of the American Medical Association</i> , 1999, 281, 151.	7.4	303
16	Evaluation of Tuberculosis Diagnostics in Children: 1. Proposed Clinical Case Definitions for Classification of Intrathoracic Tuberculosis Disease. Consensus From an Expert Panel. <i>Journal of Infectious Diseases</i> , 2012, 205, S199-S208.	4.0	275
17	Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. <i>New England Journal of Medicine</i> , 2016, 375, 1726-1737.	27.0	268
18	The Relationship between Serum Human Immunodeficiency Virus Type 1 (HIVâ€“1) RNA Level, CD4 Lymphocyte Percent, and Longâ€“Term Mortality Risk in HIVâ€“1â€“Infected Children. <i>Journal of Infectious Diseases</i> , 1997, 175, 1029-1038.	4.0	251

#	ARTICLE	IF	CITATIONS
19	Declines in Mortality Rates and Changes in Causes of Death in HIV-1-Infected Children During the HAART Era. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 53, 86-94.	2.1	249
20	Combination Therapy with Efavirenz, Nelfinavir, and Nucleoside Reverse-Transcriptase Inhibitors in Children Infected with Human Immunodeficiency Virus Type 1. <i>New England Journal of Medicine</i> , 1999, 341, 1874-1881.	27.0	228
21	Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. <i>Lancet</i> , The, 2003, 362, 1605-1611.	13.7	218
22	Disclosure of Illness Status to Children and Adolescents With HIV Infection. <i>Pediatrics</i> , 1999, 103, 164-166.	2.1	214
23	Antiretroviral Treatment for Children with Peripartum Nevirapine Exposure. <i>New England Journal of Medicine</i> , 2010, 363, 1510-1520.	27.0	210
24	Advances and research directions in the prevention of mother-to-child HIV-1 transmission. <i>Lancet</i> , The, 2000, 355, 2237-2244.	13.7	203
25	Growing Up with HIV: Children, Adolescents, and Young Adults with Perinatally Acquired HIV Infection. <i>Annual Review of Medicine</i> , 2010, 61, 169-185.	12.2	195
26	A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). <i>Aids</i> , 1999, 13, 479-486.	2.2	190
27	Three Postpartum Antiretroviral Regimens to Prevent Intrapartum HIV Infection. <i>New England Journal of Medicine</i> , 2012, 366, 2368-2379.	27.0	189
28	Safety of efavirenz in the first trimester of pregnancy. <i>Aids</i> , 2014, 28, S123-S131.	2.2	183
29	Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. <i>Aids</i> , 2000, 14, F111-F115.	2.2	180
30	Nevirapine versus Ritonavir-Boosted Lopinavir for HIV-Infected Children. <i>New England Journal of Medicine</i> , 2012, 366, 2380-2389.	27.0	172
31	Association of maternal drug use during pregnancy with maternal HIV culture positivity and perinatal HIV transmission. <i>Aids</i> , 1996, 10, 273-282.	2.2	169
32	Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis. <i>Lancet HIV</i> , the, 2017, 4, e21-e30.	4.7	163
33	A Behavioral and Cognitive Profile of Clinically Stable HIV-Infected Children. <i>Pediatrics</i> , 2006, 117, 763-770.	2.1	158
34	Efficacy of Zidovudine and Human Immunodeficiency Virus (HIV) Hyperimmune Immunoglobulin for Reducing Perinatal HIV Transmission from HIV-Infected Women with Advanced Disease: Results of Pediatric AIDS Clinical Trials Group Protocol 185. <i>Journal of Infectious Diseases</i> , 1999, 179, 567-575.	4.0	156
35	Update: Interim Guidance for the Diagnosis, Evaluation, and Management of Infants with Possible Congenital Zika Virus Infection – United States, October 2017. <i>Morbidity and Mortality Weekly Report</i> , 2017, 66, 1089-1099.	15.1	156
36	A Trial of Three Antiretroviral Regimens in HIV-1-Infected Children. <i>New England Journal of Medicine</i> , 2004, 350, 2471-2480.	27.0	145

#	ARTICLE	IF	CITATIONS
37	Cognitive Function and Neurodevelopmental Outcomes in HIV-infected Children Older Than 1 Year of Age Randomized to Early Versus Deferred Antiretroviral Therapy. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 501-508.	2.0	138
38	Risk Factors for In Utero and Intrapartum Transmission of HIV. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 38, 87-95.	2.1	133
39	First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 273-283.	9.1	123
40	In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. <i>Aids</i> , 2007, 21, 929-938.	2.2	121
41	Duration of ruptured membranes and vertical transmission of HIV-1: a meta-analysis from 15 prospective cohort studies. <i>Aids</i> , 2001, 15, 357-368.	2.2	119
42	Safety of tenofovir use during pregnancy. <i>Aids</i> , 2012, 26, 1151-1159.	2.2	118
43	Development of Resistance Mutations in Women Receiving Standard Antiretroviral Therapy Who Received Intrapartum Nevirapine to Prevent Perinatal Human Immunodeficiency Virus Type 1 Transmission: A Substudy of Pediatric AIDS Clinical Trials Group Protocol 316. <i>Journal of Infectious Diseases</i> , 2002, 186, 181-188.	4.0	117
44	Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 77, 383-392.	2.1	115
45	Challenges in the Elimination of Pediatric HIV-1 Infection. <i>New England Journal of Medicine</i> , 2016, 374, 761-770.	27.0	112
46	Update: Interim Guidance for the Evaluation and Management of Infants with Possible Congenital Zika Virus Infection – United States, August 2016. <i>Morbidity and Mortality Weekly Report</i> , 2016, 65, 870-878.	15.1	111
47	Prevention in Neglected Subpopulations: Prevention of Mother-to-Child Transmission of HIV Infection. <i>Clinical Infectious Diseases</i> , 2010, 50, S130-S148.	5.8	110
48	A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naïve HIV-1 infection. <i>Journal of Pediatrics</i> , 1998, 133, 500-508.	1.8	108
49	Safety of efavirenz in the first trimester of pregnancy. <i>Aids</i> , 2011, 25, 2301-2304.	2.2	108
50	Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , The, 2012, 379, 221-228.	13.7	108
51	Lack of Tumors in Infants With Perinatal HIV-1 Exposure and Fetal/Neonatal Exposure to Zidovudine. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999, 20, 463-467.	0.3	107
52	Pharmacokinetics of Saquinavir plus Low-Dose Ritonavir in Human Immunodeficiency Virus-Infected Pregnant Women. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 430-436.	3.2	107
53	Effect of Perinatal Antiretroviral Drug Exposure on Hematologic Values in HIV-Uninfected Children: An Analysis of the Women and Infants Transmission Study. <i>Journal of Infectious Diseases</i> , 2006, 194, 1089-1097.	4.0	107
54	Combination Antiretroviral Use and Preterm Birth. <i>Journal of Infectious Diseases</i> , 2013, 207, 612-621.	4.0	107

#	ARTICLE	IF	CITATIONS
55	Diagnosis of HIV-1 Infection in Children Younger Than 18 Months in the United States. <i>Pediatrics</i> , 2007, 120, e1547-e1562.	2.1	106
56	Frequency of Gastroenteritis and Gastroenteritis-Associated Mortality With Early Weaning in HIV-1-Uninfected Children Born to HIV-Infected Women in Malawi. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 53, 6-13.	2.1	106
57	Adolescents and HIV Infection: The Pediatrician's Role in Promoting Routine Testing. <i>Pediatrics</i> , 2011, 128, 1023-1029.	2.1	101
58	The epidemiology of adolescents living with perinatally acquired HIV: A cross-region global cohort analysis. <i>PLoS Medicine</i> , 2018, 15, e1002514.	8.4	98
59	Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316. <i>American Journal of Obstetrics and Gynecology</i> , 2004, 190, 506-516.	1.3	97
60	Lower Newborn Bone Mineral Content Associated With Maternal Use of Tenofovir Disoproxil Fumarate During Pregnancy. <i>Clinical Infectious Diseases</i> , 2015, 61, 996-1003.	5.8	97
61	U.S. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. <i>MMWR Recommendations and Reports</i> , 2002, 51, 1-38; quiz CE1-4.	61.1	97
62	Pharmacokinetics and tolerance of zidovudine in preterm infants. <i>Journal of Pediatrics</i> , 2003, 142, 47-52.	1.8	96
63	Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. <i>Aids</i> , 2010, 24, 1461-1470.	2.2	94
64	Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. <i>Aids</i> , 2017, 31, 213-232.	2.2	93
65	The challenges of success: adolescents with perinatal HIV infection. <i>Journal of the International AIDS Society</i> , 2013, 16, 18650.	3.0	90
66	Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. <i>MMWR Recommendations and Reports</i> , 2009, 58, 1-166.	61.1	90
67	Performance Characteristics of HIV-1 Culture and HIV-1 DNA and RNA Amplification Assays for Early Diagnosis of Perinatal HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 34, 512-519.	2.1	89
68	Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 2419-2428.	1.4	87
69	Safety of Antiretroviral Prophylaxis of Perinatal Transmission for HIV-Infected Pregnant Women and Their Infants. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2002, 30, 200-215.	2.1	86
70	Maternal and Infant Factors Predicting Disease Progression in Human Immunodeficiency Virus Type 1-Infected Infants. <i>Pediatrics</i> , 2000, 105, e8-e8.	2.1	82
71	Outcomes of Antiretroviral Therapy in Children in Asia and Africa. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2013, 62, 208-219.	2.1	81
72	MOTHER-CHILD HIV-1 TRANSMISSION. <i>Obstetrics and Gynecology Clinics of North America</i> , 1997, 24, 759-784.	1.9	79

#	ARTICLE	IF	CITATIONS
73	Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. <i>Lancet Infectious Diseases</i> , The, 2012, 12, 933-941.	9.1	78
74	Dynamics of Human Immunodeficiency Virus Type 1 Replication in Vertically Infected Infants. <i>Journal of Virology</i> , 1999, 73, 362-367.	3.4	78
75	Neurodevelopment and In Utero Antiretroviral Exposure of HIV-Exposed Uninfected Infants. <i>Pediatrics</i> , 2010, 125, e250-e260.	2.1	77
76	Antiretroviral Drugs for Preventing Mother-to-Child Transmission of HIV: A Review of Potential Effects on HIV-Exposed but Uninfected Children. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 57, 290-296.	2.1	76
77	Pharmacokinetics and Safety of Indinavir in Human Immunodeficiency Virus-Infected Pregnant Women. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 783-786.	3.2	75
78	Safety of 2 Recombinant Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Vaccines in Neonates Born to HIV-1-Infected Women. <i>Clinical Infectious Diseases</i> , 2001, 32, 801-807.	5.8	73
79	Treating Opportunistic Infections among HIV-Exposed and Infected Children: Recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2005, 40, S1-S84.	5.8	73
80	Progression of HIV Disease Among Women Following Delivery. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 33, 585-593.	2.1	71
81	Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2017, 76, 1-12.	2.1	71
82	Concentrations of protease inhibitors in cord blood after in utero exposure. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 835-838.	2.0	69
83	Antiretroviral Treatment of US Children With Perinatally Acquired HIV Infection: Temporal Changes in Therapy Between 1991 and 2009 and Predictors of Immunologic and Virologic Outcomes. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 57, 165-173.	2.1	69
84	Chlamydia and Gonorrhea in HIV-Infected Pregnant Women and Infant HIV Transmission. <i>Sexually Transmitted Diseases</i> , 2015, 42, 554-565.	1.7	68
85	Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. <i>Aids</i> , 2000, 14, 1389-1399.	2.2	67
86	Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading?. <i>Journal of the International AIDS Society</i> , 2020, 23, e25426.	3.0	67
87	Protecting the Next Generation – Eliminating Perinatal HIV-1 Infection. <i>New England Journal of Medicine</i> , 2010, 362, 2316-2318.	27.0	64
88	Advances in the prevention of vertical transmission of human immunodeficiency virus. <i>Seminars in Pediatric Infectious Diseases</i> , 2003, 14, 295-308.	1.7	63
89	Antiretroviral Therapy and Adverse Pregnancy Outcome: The Elephant in the Room?. <i>Journal of Infectious Diseases</i> , 2016, 213, 1051-1054.	4.0	62
90	Infant Feeding and Transmission of Human Immunodeficiency Virus in the United States. <i>Pediatrics</i> , 2013, 131, 391-396.	2.1	60

#	ARTICLE	IF	CITATIONS
91	Pharmacokinetics and Safety of Tenofovir in HIV-Infected Women During Labor and Their Infants During the First Week of Life. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 65, 33-41.	2.1	60
92	Safety and Trough Concentrations of Nevirapine Prophylaxis Given Daily, Twice Weekly, or Weekly in Breast-Feeding Infants From Birth to 6 Months. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 34, 482-490.	2.1	59
93	International recommendations on antiretroviral drugs for treatment of HIV-infected women and prevention of mother-to-child HIV transmission in resource-limited settings: 2006 update. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, S42-S55.	1.3	59
94	Progress, Challenges, and New Opportunities for the Prevention of Mother-to-Child Transmission of HIV Under the US President's Emergency Plan for AIDS Relief. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 60, S78-S87.	2.1	59
95	Prophylactic Intravenous Immunoglobulin in HIV-Infected Children With CD4+ Counts of 0.20–109/L or More. <i>JAMA - Journal of the American Medical Association</i> , 1992, 268, 483.	7.4	57
96	Zidovudine for the reduction of perinatal human immunodeficiency virus transmission. <i>Pediatric Infectious Disease Journal</i> , 1995, 14, 536-541.	2.0	57
97	Human Immunodeficiency Virus Type 1 (HIV-1) gp120-Specific Antibodies in Neonates Receiving an HIV-1 Recombinant gp120 Vaccine. <i>Journal of Infectious Diseases</i> , 2001, 184, 1331-1335.	4.0	57
98	Predose Infant Nevirapine Concentration With the Two-Dose Intrapartum Neonatal Nevirapine Regimen: Association With Timing of Maternal Intrapartum Nevirapine Dose. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 33, 153-156.	2.1	56
99	Postnatal HIV-1 Transmission after Cessation of Infant Extended Antiretroviral Prophylaxis and Effect of Maternal Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2009, 200, 1490-1497.	4.0	55
100	Lymphoproliferative Responses to Recombinant HIV-1 Envelope Antigens in Neonates and Infants Receiving gp120 Vaccines. <i>Journal of Infectious Diseases</i> , 2000, 181, 890-896.	4.0	54
101	Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis. <i>EClinicalMedicine</i> , 2020, 28, 100573.	7.1	54
102	Short-course zidovudine for prevention of perinatal infection. <i>Lancet</i> , The, 1999, 353, 766-767.	13.7	53
103	Pharmacokinetics and Safety of Single-Dose Tenofovir Disoproxil Fumarate and Emtricitabine in HIV-1-Infected Pregnant Women and Their Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 5914-5922.	3.2	53
104	Syphilis in HIV-infected Mothers and Infants. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, e52-e57.	2.0	53
105	Updates to the Spectrum/AIM model for estimating key HIV indicators at national and subnational levels. <i>Aids</i> , 2019, 33, S227-S234.	2.2	52
106	Effect of Cessation of Zidovudine Prophylaxis to Reduce Vertical Transmission on Maternal HIV Disease Progression and Survival. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 32, 170-181.	2.1	51
107	Estimates of peripartum and postnatal mother-to-child transmission probabilities of HIV for use in Spectrum and other population-based models. <i>Sexually Transmitted Infections</i> , 2012, 88, i44-i51.	1.9	51
108	Breast-Milk Shedding of Drug-Resistant HIV-1 Subtype C in Women Exposed to Single-Dose Nevirapine. <i>Journal of Infectious Diseases</i> , 2005, 192, 1260-1264.	4.0	50



#	ARTICLE	IF	CITATIONS
109	Antiretroviral drugs to prevent breastfeeding HIV transmission. <i>Antiviral Therapy</i> , 2010, 15, 537-553.	1.0	50
110	Effects of Cessation of Breastfeeding in HIV-1-Exposed, Uninfected Children in Malawi. <i>Clinical Infectious Diseases</i> , 2011, 53, 388-395.	5.8	50
111	Pharmacokinetics of Saquinavir-SGC in HIV-Infected Pregnant Women. <i>HIV Clinical Trials</i> , 2001, 2, 460-465.	2.0	49
112	Long Term Tolerability and Safety of Enfuvirtide for Human Immunodeficiency Virus 1-Infected Children. <i>Pediatric Infectious Disease Journal</i> , 2004, 23, 713-718.	2.0	49
113	Antiretroviral Prophylaxis of Perinatal HIV-1 Transmission and the Potential Impact of Antiretroviral Resistance. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 30, 216-229.	2.1	47
114	Recommendations for human immunodeficiency virus screening, prophylaxis, and treatment for pregnant women in the United States. <i>American Journal of Obstetrics and Gynecology</i> , 2007, 197, S26-S32.	1.3	47
115	Nevirapine Concentrations in Newborns Receiving an Extended Prophylactic Regimen. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 334-337.	2.1	47
116	Initiation of Antiretroviral Treatment in Women After Delivery Can Induce Multiclass Drug Resistance in Breastfeeding HIV-Infected Infants. <i>Clinical Infectious Diseases</i> , 2011, 52, 1069-1076.	5.8	47
117	Improving estimates of children living with HIV from the Spectrum AIDS Impact Model. <i>Aids</i> , 2017, 31, S13-S22.	2.2	47
118	Can Perinatal HIV Infection Be Eliminated in the United States?. <i>JAMA - Journal of the American Medical Association</i> , 1999, 282, 577.	7.4	46
119	Adolescents and Human Immunodeficiency Virus Infection: The Role of the Pediatrician in Prevention and Intervention. <i>Pediatrics</i> , 2001, 107, 188-190.	2.1	46
120	Safety and antiretroviral activity of chronic subcutaneous administration of T-20 in human immunodeficiency virus 1-infected children. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 653-659.	2.0	46
121	Successes and Challenges in the Perinatal HIV-1 Epidemic in the United States as Illustrated by the HIV-1 Serosurvey of Childbearing Women. <i>JAMA Pediatrics</i> , 2004, 158, 422.	3.0	46
122	Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, i.	2.0	46
123	<i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> in HIV-infected Pregnant Women and Adverse Infant Outcomes. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 894-900.	2.0	46
124	Evaluation and Medical Treatment of the HIV-Exposed Infant. <i>Pediatrics</i> , 1997, 99, 909-917.	2.1	45
125	Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource-poor settings. <i>Lancet, The</i> , 2003, 362, 1625-1627.	13.7	45
126	Evaluation and Management of the Infant Exposed to HIV-1 in the United States. <i>Pediatrics</i> , 2009, 123, 175-187.	2.1	45



#	ARTICLE	IF	CITATIONS
127	A critical review of studies evaluating the relationship of mode of delivery to perinatal transmission of human immunodeficiency virus. <i>Pediatric Infectious Disease Journal</i> , 1995, 14, 169-177.	2.0	44
128	Tenofovir Treatment Duration Predicts Proteinuria in a Multiethnic United States Cohort of Children and Adolescents With Perinatal HIV-1 Infection. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 495-500.	2.0	44
129	Defining gaps in pre-exposure prophylaxis delivery for pregnant and post-partum women in high-burden settings using an implementation science framework. <i>Lancet HIV</i> , 2020, 7, e582-e592.	4.7	44
130	Assessment of Clinical Outcomes Among Children and Adolescents Hospitalized With COVID-19 in 6 Sub-Saharan African Countries. <i>JAMA Pediatrics</i> , 2022, 176, e216436.	6.2	44
131	Pharmacokinetics and Safety of Nelfinavir When Used in Combination with Zidovudine and Lamivudine in HIV-Infected Pregnant Women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. <i>HIV Clinical Trials</i> , 2008, 9, 115-125.	2.0	43
132	Toward Earlier Inclusion of Pregnant and Postpartum Women in Tuberculosis Drug Trials: Consensus Statements From an International Expert Panel. <i>Clinical Infectious Diseases</i> , 2016, 62, 761-769.	5.8	43
133	A Multi-Disciplinary Approach to Implementation Science. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, S163-S167.	2.1	42
134	Combined evaluation of sexually transmitted infections in HIV-infected pregnant women and infant HIV transmission. <i>PLoS ONE</i> , 2018, 13, e0189851.	2.5	42
135	Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2015, 70, 33-41.	2.1	41
136	Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. <i>Clinical Infectious Diseases</i> , 2016, 63, 1113-1121.	5.8	41
137	Achieving Viral Suppression in 90% of People Living With Human Immunodeficiency Virus on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities. <i>Clinical Infectious Diseases</i> , 2018, 66, 1487-1491.	5.8	41
138	Osteonecrosis of the Hip (Legg-Calve-Perthes Disease) in Human Immunodeficiency Virus-Infected Children. <i>Pediatrics</i> , 2002, 109, e74-e74.	2.1	40
139	Maternal viral load and rate of disease progression among vertically HIV-1-infected children. <i>Aids</i> , 2004, 18, 99-108.	2.2	40
140	Pharmacokinetics and Pharmacodynamics of Efavirenz and Nelfinavir in HIV-infected Children Participating in an Area-under-the-curve Controlled Trial. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 300-306.	4.7	40
141	Measles Immunization in HIV-Infected Children. <i>Pediatrics</i> , 1999, 103, 1057-1060.	2.1	39
142	Clinical manifestations, prevalence, risk factors, outcomes, transmission, diagnosis and treatment of COVID-19 in pregnancy and postpartum: a living systematic review protocol. <i>BMJ Open</i> , 2020, 10, e041868.	1.9	39
143	Growth in Human Immunodeficiency Virus-Infected Children Receiving Ritonavir-Containing Antiretroviral Therapy. <i>JAMA Pediatrics</i> , 2002, 156, 497.	3.0	38
144	Raltegravir Pharmacokinetics in Neonates Following Maternal Dosing. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 67, 310-315.	2.1	38

#	ARTICLE	IF	CITATIONS
145	Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn Infants. <i>Journal of Infectious Diseases</i> , 2020, 222, 628-636.	4.0	38
146	Perinatal Exposure to Zidovudine – Benefits and Risks. <i>New England Journal of Medicine</i> , 2000, 343, 803-805.	27.0	37
147	Tale of Two Epidemics – The Continuing Challenge of Preventing Mother-to-Child Transmission of Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2003, 187, 721-724.	4.0	37
148	Serum HIV-1 p24 antibody, HIV-1 RNA copy number and CD4 lymphocyte percentage are independently associated with risk of mortality in HIV-1-infected children. <i>Aids</i> , 1999, 13, 31-39.	2.2	37
149	Paediatric HIV-1 infection. <i>Lancet, The</i> , 1999, 354, S11-S16.	13.7	36
150	Pharmacokinetics and Safety of Stavudine in HIV-1-Infected Pregnant Women and Their Infants: Pediatric AIDS Clinical Trials Group Protocol 332. <i>Journal of Infectious Diseases</i> , 2004, 190, 2167-2174.	4.0	36
151	Nelfinavir and Lamivudine Pharmacokinetics During the First Two Weeks of Life. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 769-772.	2.0	36
152	Postexposure Prophylaxis of Breastfeeding HIV-Exposed Infants With Antiretroviral Drugs to Age 14 Weeks: Updated Efficacy Results of the PÉPI-Malawi Trial. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 57, 319-325.	2.1	36
153	A Trigger-based Design for Evaluating the Safety of In Utero Antiretroviral Exposure in Uninfected Children of Human Immunodeficiency Virus-Infected Mothers. <i>American Journal of Epidemiology</i> , 2012, 175, 950-961.	3.4	36
154	Antiretroviral Prophylaxis to Reduce Breast Milk Transmission of HIV Type 1: New Data but Still Questions. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 48, 237-240.	2.1	35
155	Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. <i>Journal of Perinatal Medicine</i> , 2011, 39, 163-70.	1.4	35
156	New Challenges in the Elimination of Pediatric HIV Infection: The Expanding Population of HIV-Affected but Uninfected Children. <i>Clinical Infectious Diseases</i> , 2015, 60, 1357-60.	5.8	35
157	Youth engagement in developing an implementation science research agenda on adolescent HIV testing and care linkages in sub-Saharan Africa. <i>Aids</i> , 2017, 31, S195-S201.	2.2	34
158	The role of obstetric interventions in the prevention of pediatric human immunodeficiency virus infection. <i>American Journal of Obstetrics and Gynecology</i> , 1994, 171, 1167-1175.	1.3	33
159	Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. <i>Pediatric Infectious Disease Journal</i> , 2001, 20, 746-751.	2.0	33
160	Risk factors for Kaposi's sarcoma-associated herpesvirus infection among HIV-1-infected pregnant women in the USA. <i>Aids</i> , 2003, 17, 425-433.	2.2	32
161	Patterns of Plasma Human Immunodeficiency Virus Type 1 RNA Response to Highly Active Antiretroviral Therapy in Infected Children. <i>Journal of Infectious Diseases</i> , 2000, 182, 1769-1773.	4.0	31
162	Impact of Maternal and Infant Antiretroviral Drug Regimens on Drug Resistance in HIV-infected Breastfeeding Infants. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, e164-e169.	2.0	31

#	ARTICLE	IF	CITATIONS
163	Early Combination Antiretroviral Therapy Limits Exposure to HIV-1 Replication and Cell-Associated HIV-1 DNA Levels in Infants. <i>PLoS ONE</i> , 2016, 11, e0154391.	2.5	31
164	Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. <i>Pediatric Infectious Disease</i> , 1994, 13, 477-484.	0.8	30
165	Use of Human Immunodeficiency Virus (HIV) Human Hyperimmune Immunoglobulin in HIV Type 1â€“Infected Children (Pediatric AIDS Clinical Trials Group Protocol 273). <i>Journal of Infectious Diseases</i> , 2000, 181, 548-554.	4.0	30
166	Brief Report: APOL1 Renal Risk Variants Are Associated With Chronic Kidney Disease in Children and Youth With Perinatal HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 73, 63-68.	2.1	30
167	Sinusitis in Children Infected with Human Immunodeficiency Virus: Clinical Characteristics, Risk Factors, and Prophylaxis. <i>Clinical Infectious Diseases</i> , 1995, 21, 1175-1181.	5.8	29
168	Human Immunodeficiency Virus, Mycobacterium Tuberculosis, and Pregnancy: A Deadly Combination. <i>Clinical Infectious Diseases</i> , 2007, 45, 250-253.	5.8	29
169	HIV Monoclonal Antibodies: A New Opportunity to Further Reduce Mother-to-Child HIV Transmission. <i>PLoS Medicine</i> , 2014, 11, e1001616.	8.4	29
170	Characteristics of acute pneumonia in human immunodeficiency virus-infected children and association with long term mortality risk. <i>Pediatric Infectious Disease Journal</i> , 1998, 17, 872-880.	2.0	29
171	Evaluation of Pharmacokinetics, Safety, Tolerance, and Activity of Combination of Zalcitabine and Zidovudine in Stable, Zidovudineâ€“Treated Pediatric Patients with Human Immunodeficiency Virus Infection. <i>Journal of Infectious Diseases</i> , 1997, 175, 1039-1050.	4.0	28
172	Safety of Cotrimoxazole in Pregnancy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 512-521.	2.1	28
173	Cardiac effects of in-utero exposure to antiretroviral therapy in HIV-uninfected children born to HIV-infected mothers. <i>Aids</i> , 2015, 29, 91-100.	2.2	28
174	Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list. <i>Lancet HIV</i> , the, 2019, 6, e623-e631.	4.7	27
175	Early neurodevelopmental markers predictive of mortality in infants infected with HIVâ€“1. <i>Developmental Medicine and Child Neurology</i> , 2003, 45, 76-84.	2.1	26
176	Safety of Pediatric HIV Elimination: The Growing Population of HIV- and Antiretroviral-Exposed but Uninfected Infants. <i>PLoS Medicine</i> , 2014, 11, e1001636.	8.4	26
177	Optimizing Research to Speed Up Availability of Pediatric Antiretroviral Drugs and Formulations. <i>Clinical Infectious Diseases</i> , 2017, 64, 1597-1603.	5.8	26
178	Congenital Cytomegalovirus and HIV Perinatal Transmission. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 1016-1021.	2.0	26
179	Tenofovir Pre-exposure Prophylaxis for Pregnant and Breastfeeding Women at Risk of HIV Infection: The Time is Now. <i>PLoS Medicine</i> , 2016, 13, e1002133.	8.4	26
180	Planning for Children Whose Parents Are Dying of HIV/AIDS. <i>Pediatrics</i> , 1999, 103, 509-511.	2.1	25

#	ARTICLE	IF	CITATIONS
181	Male Circumcision for Prevention of HIV and Other Sexually Transmitted Diseases. <i>Pediatrics</i> , 2007, 119, 821-822.	2.1	25
182	Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects. <i>Journal of the International AIDS Society</i> , 2019, 22, e25352.	3.0	25
183	Accelerating progress towards the elimination of mother-to-child transmission of HIV: a narrative review. <i>Journal of the International AIDS Society</i> , 2020, 23, e25571.	3.0	25
184	Immunologic Targets of HIV Infection: T Cells. <i>Annals of the New York Academy of Sciences</i> , 1993, 693, 35-51.	3.8	24
185	Unresolved Antiretroviral Treatment Management Issues in HIV-Infected Children. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 161-169.	2.1	24
186	Efficacy and Safety of an Extended Nevirapine Regimen in Infants of Breastfeeding Mothers With HIV-1 Infection for Prevention of HIV-1 Transmission (HPTN 046). <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 65, 366-374.	2.1	24
187	Toxicity and efficacy of daily vs. weekly dapsone for prevention of <i>Pneumocystis carinii</i> pneumonia in children infected with human immunodeficiency virus. <i>Pediatric Infectious Disease Journal</i> , 1999, 18, 432-439.	2.0	24
188	Intravenous Immune Globulin for the Prevention of Infections in Children with Symptomatic Human Immunodeficiency Virus Infection. <i>Pediatric Research</i> , 1993, 33, S80-S89.	2.3	23
189	Hepatitis C Prevalence in Children With Perinatal Human Immunodeficiency Virus Infection Enrolled in a Long-term Follow-up Protocol. <i>JAMA Pediatrics</i> , 2004, 158, 1007.	3.0	23
190	Clinical Response and Tolerability to and Safety of Saquinavir with Low-Dose Ritonavir in Human Immunodeficiency Virus Type 1-Infected Mothers and Their Infants. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 2208-2210.	3.2	23
191	Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 $\geq$ 400 cells/mm <sup>3</sup> . <i>PLoS ONE</i> , 2017, 12, e0176009.	2.5	23
192	The Interface of Perinatal HIV Prevention, Antiretroviral Drug Resistance, and Antiretroviral Treatment: What Do We Really Know?. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2003, 34, 308-311.	2.1	22
193	Antiretrovirals in Pregnancy: A Note of Caution. <i>Journal of Infectious Diseases</i> , 2012, 206, 1639-1641.	4.0	22
194	Assessing Very Early Infant Diagnosis Turnaround Times: Findings from a Birth Testing Pilot in Lesotho. <i>AIDS Research and Treatment</i> , 2017, 2017, 1-8.	0.7	22
195	Infectious Morbidity, Mortality and Nutrition in HIV-exposed, Uninfected, Formula-fed Infants. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 1271-1278.	2.0	22
196	Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration. <i>Lancet HIV</i> , 2019, 6, e105-e115.	4.7	22
197	Association of Maternal Viral Load and CD4 Count With Perinatal HIV-1 Transmission Risk During Breastfeeding in the PROMISE Postpartum Component. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2021, 88, 206-213.	2.1	22
198	Cytomegalovirus Urinary Shedding in HIV-infected Pregnant Women and Congenital Cytomegalovirus Infection. <i>Clinical Infectious Diseases</i> , 2017, 65, 405-413.	5.8	21

#	ARTICLE	IF	CITATIONS
199	Maternal Drug Use in Perinatal HIV Studies: The Women and Infants Transmission Study. <i>Annals of the New York Academy of Sciences</i> , 1993, 693, 245-248.	3.8	20
200	Time to First-Line ART Failure and Time to Second-Line ART Switch in the IeDEA Pediatric Cohort. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2018, 78, 221-230.	2.1	20
201	Combination Therapy With Stavudine (d4T) Plus Didanosine (ddl) in Children With Human Immunodeficiency Virus Infection. <i>Pediatrics</i> , 1999, 103, e62-e62.	2.1	19
202	Antimicrobial-Specific Cell-Mediated Immune Reconstitution in Children with Advanced Human Immunodeficiency Virus Infection Receiving Highly Active Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2004, 39, 107-114.	5.8	19
203	Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero. <i>Aids</i> , 2010, 24, 381-386.	2.2	19
204	Pooled Individual Data Analysis of 5 Randomized Trials of Infant Nevirapine Prophylaxis to Prevent Breast-Milk HIV-1 Transmission. <i>Clinical Infectious Diseases</i> , 2013, 56, 131-139.	5.8	19
205	Long-term Safety and Efficacy of Atazanavir-based Therapy in HIV-infected Infants, Children and Adolescents. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 162-167.	2.0	19
206	Treatment of COVID-19 in pregnant women: A systematic review and meta-analysis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 267, 120-128.	1.1	19
207	Passive immunization to prevent mother-infant transmission of human immunodeficiency virus. <i>Pediatric Infectious Disease Journal</i> , 1991, 10, 456-462.	2.0	18
208	Immune Reconstitution after Receipt of Highly Active Antiretroviral Therapy in Children with Advanced or Progressive HIV Disease and Complete or Partial Viral Load Response. <i>Journal of Infectious Diseases</i> , 2005, 192, 296-302.	4.0	18
209	Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents. <i>Aids</i> , 2011, 25, 1489-1496.	2.2	18
210	Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis. <i>Aids</i> , 2011, 25, 911-917.	2.2	18
211	Elevated CD8+DR+ Lymphocytes in HIV-Exposed Infants With Early Positive HIV Cultures. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 15, 204-210.	0.3	18
212	World Health Organization Generic Protocol to Assess Drug-Resistant HIV Among Children < 18 Months of Age and Newly Diagnosed With HIV in Resource-Limited Countries. <i>Clinical Infectious Diseases</i> , 2012, 54, S254-S260.	5.8	17
213	Risk of HIV Acquisition During Pregnancy and Postpartum: A Call for Action. <i>Journal of Infectious Diseases</i> , 2018, 218, 1-4.	4.0	17
214	Human Immunodeficiency Virus Antiretroviral Resistance and Transmission in Mother-Infant Pairs Enrolled in a Large Perinatal Study. <i>Clinical Infectious Diseases</i> , 2018, 66, 1770-1777.	5.8	17
215	Effect of SARS-CoV-2 Infection in Pregnancy on Maternal and Neonatal Outcomes in Africa: An AFREhealth Call for Evidence through Multicountry Research Collaboration. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, , .	1.4	17
216	Human Immunodeficiency Virus Infection in Pregnant Women Under Care at AIDS Clinical Trials Centers in the United States. <i>Obstetrics and Gynecology</i> , 1992, 79, 364-368.	2.4	16

#	ARTICLE	IF	CITATIONS
217	Maternal and pediatric AIDS in the United States: the current situation and future research directions. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 1994, 83, 106-110.	1.5	16
218	Human Immunodeficiency Virus (HIV) Type 1 Antibodies in Perinatal HIV Infection: Association with Human HIV Transmission, Infection, and Disease Progression. <i>Journal of Infectious Diseases</i> , 2000, 182, 1243-1246.	4.0	16
219	Plasma Drug Concentrations and Virologic Evaluations after Stopping Treatment with Nonnucleoside Reverse Transcriptase Inhibitors in HIV Type 1 Infected Children. <i>Clinical Infectious Diseases</i> , 2008, 46, 1601-1608.	5.8	16
220	Viral Load Predicts New World Health Organization Stage 3 and 4 Events in HIV Infected Children Receiving Highly Active Antiretroviral Therapy, Independent of CD4 T Lymphocyte Value. <i>Clinical Infectious Diseases</i> , 2010, 51, 1325-1333.	5.8	16
221	Predictors of Virologic and Clinical Response to Nevirapine versus Lopinavir/Ritonavir-based Antiretroviral Therapy in Young Children With and Without Prior Nevirapine Exposure for the Prevention of Mother-to-child HIV Transmission. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 846-854.	2.0	16
222	Ending the evidence gap for pregnancy, HIV and co-infections: ethics guidance from the PHASES project. <i>Journal of the International AIDS Society</i> , 2021, 24, e25846.	3.0	16
223	Prevention of Mother-to-Child HIV-1 Transmission—Why We Still Need a Preventive HIV Immunization Strategy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 58, 359-362.	2.1	15
224	Infant Outcomes After Maternal Antiretroviral Exposure in Resource-Limited Settings. <i>Pediatrics</i> , 2012, 129, e1525-e1532.	2.1	15
225	24-month HIV-free survival among infants born to HIV-positive women enrolled in Option B+ program in Kigali, Rwanda. <i>Medicine (United States)</i> , 2017, 96, e9445.	1.0	15
226	Enhanced and Timely Investigation of ARVs for Use in Pregnant Women. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 607-615.	2.1	15
227	Scaling Up Covid-19 Vaccination in Africa—Lessons from the HIV Pandemic. <i>New England Journal of Medicine</i> , 2021, 385, 196-198.	27.0	15
228	The Impact of Race/Ethnicity on Mother-to-Child HIV Transmission in the United States in Pediatric AIDS Clinical Trials Group Protocol 316. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 800-807.	2.1	14
229	Tuberculosis in Pediatric Antiretroviral Therapy Programs in Low- and Middle-Income Countries: Diagnosis and Screening Practices. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, 30-38.	1.3	14
230	In-utero ART exposure and the need for pharmacovigilance. <i>The Lancet Global Health</i> , 2018, 6, e716-e717.	6.3	14
231	Challenges in the Early Infant HIV Diagnosis and Treatment Cascade. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 84, S1-S4.	2.1	14
232	The Critical Need for Pooled Data on Coronavirus Disease 2019 in African Children: An AFREhealth Call for Action Through Multicountry Research Collaboration. <i>Clinical Infectious Diseases</i> , 2021, 73, 1913-1919.	5.8	14
233	Pharmacokinetics of Dapsone Administered Daily and Weekly in Human Immunodeficiency Virus-Infected Children. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2586-2591.	3.2	14
234	Piloting very early infant diagnosis of HIV in Lesotho: Acceptability and feasibility among mothers, health workers and laboratory personnel. <i>PLoS ONE</i> , 2018, 13, e0190874.	2.5	14



#	ARTICLE	IF	CITATIONS
235	Nevirapine concentrations in newborns receiving an extended prophylactic regimen. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2008, 47, 334-7.	2.1	14
236	Perinatally acquired human immunodeficiency virus infection. <i>Pediatric Infectious Disease Journal</i> , 1992, 11, 941-945.	2.0	13
237	ANTIRETROVIRAL THERAPY AND INTERRUPTION OF HIV PERINATAL TRANSMISSION. <i>Immunology and Allergy Clinics of North America</i> , 1998, 18, 441-463.	1.9	13
238	Quantification of human immunodeficiency virus type 1 p24 antigen and antibody rivals human immunodeficiency virus type 1 RNA and CD4+ enumeration for prognosis. <i>Pediatric Infectious Disease Journal</i> , 2000, 19, 544-551.	2.0	13
239	Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy. <i>Clinical Infectious Diseases</i> , 2020, 70, 2599-2606.	5.8	13
240	Adverse Pregnancy Outcomes Among HIV-positive Women in the Era of Universal Antiretroviral Therapy Remain Elevated Compared With HIV-negative Women. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, 821-826.	2.0	13
241	Serum vitamin A concentrations in a North American cohort of human immunodeficiency virus type 1-infected children. <i>Pediatric Infectious Disease Journal</i> , 1999, 18, 134-142.	2.0	13
242	Conventional early infant diagnosis in Lesotho from specimen collection to results usage to manage patients: Where are the bottlenecks?. <i>PLoS ONE</i> , 2017, 12, e0184769.	2.5	13
243	Prevention of Breast Milk Transmission of HIV: The Time Is Now. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 52, 305-308.	2.1	12
244	Children born into families affected by HIV. <i>Aids</i> , 2014, 28, S241-S244.	2.2	12
245	Reducing CD4 Monitoring in Children on Antiretroviral Therapy With Virologic Suppression. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 1361-1364.	2.0	12
246	Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection. <i>Pediatric Infectious Disease Journal</i> , 2002, 21, 119-125.	2.0	12
247	Immune Parameters and Morbidity in Hard Drug and Human Immunodeficiency Virus-exposed but Uninfected Infants. <i>Pediatrics</i> , 2004, 113, 1260-1266.	2.1	11
248	Pharmacokinetics of oral zidovudine administered during labour: a preliminary study. <i>HIV Medicine</i> , 2007, 8, 451-456.	2.2	11
249	Point-of-care Capillary Blood Lactate Measurements in Human Immunodeficiency Virus-uninfected Children With In Utero Exposure to Human Immunodeficiency Virus and Antiretroviral Medications. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 1069-1074.	2.0	11
250	Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060. <i>PLoS ONE</i> , 2016, 11, e0165140.	2.5	11
251	Association of Antiretroviral Drug Regimen With Viral Suppression in HIV-positive Children on Antiretroviral Therapy in Eswatini. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 835-839.	2.0	11
252	Pharmacokinetics of Increased Nelfinavir Plasma Concentrations in Women During Pregnancy and Postpartum. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 386-393.	2.0	11



#	ARTICLE	IF	CITATIONS
253	Surveillance of Pediatric HIV Infection. <i>Pediatrics</i> , 1998, 101, 315-319.	2.1	11
254	GB Virus C Infection in Children With Perinatal Human Immunodeficiency Virus Infection. <i>Pediatric Infectious Disease Journal</i> , 2005, 24, 417-422.	2.0	10
255	Impact of GB virus type C infection on mother-to-child HIV transmission in the Women and Infants Transmission Study Cohort. <i>HIV Medicine</i> , 2007, 8, 561-567.	2.2	10
256	Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial. <i>BMC Pregnancy and Childbirth</i> , 2019, 19, 81.	2.4	10
257	Potential Confounding of the Association Between Exposure to Nucleoside Analogues and Mitochondrial Dysfunction in HIV-Uninfected and Indeterminate Infants. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 154-157.	2.1	9
258	Protecting the health of our AIDS-free generation. <i>Aids</i> , 2017, 31, 315-316.	2.2	9
259	More on Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China. <i>New England Journal of Medicine</i> , 2020, 383, 696-697.	27.0	9
260	Safety and pharmacokinetics of nelfinavir coadministered with zidovudine and lamivudine in infants during the first 6 weeks of life. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 39, 189-94.	2.1	9
261	Population pharmacokinetics of dapson in children with human immunodeficiency virus infection. <i>Clinical Pharmacology and Therapeutics</i> , 2001, 70, 24-32.	4.7	8
262	Prevention of mother-to-child HIV transmission. <i>Current Opinion in HIV and AIDS</i> , 2013, 8, 443-446.	3.8	8
263	Creating Sustainable Collaborations for Implementation Science: The Case of the NIH-PEPFAR PMTCT Implementation Science Alliance. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 72, S102-S107.	2.1	8
264	Recent progress in immune-based interventions to prevent HIV-1 transmission to children. <i>Journal of the International AIDS Society</i> , 2017, 20, e25038.	3.0	8
265	Estimating the cost of diagnosing HIV at birth in Lesotho. <i>PLoS ONE</i> , 2018, 13, e0202420.	2.5	8
266	Growth and CD4 patterns of adolescents living with perinatally acquired HIV worldwide, a CIPHER cohort collaboration analysis. <i>Journal of the International AIDS Society</i> , 2022, 25, e25871.	3.0	8
267	Surveillance of ARV safety in pregnancy and breastfeeding: towards a new framework. <i>Journal of the International AIDS Society</i> , 2022, 25, .	3.0	8
268	Effects of Polymorphisms of Chemokine Receptors on Neurodevelopment and the Onset of Encephalopathy in Children with Perinatal HIV-1 Infection. <i>Applied Neuropsychology</i> , 2006, 13, 180-189.	1.5	7
269	Early antiretroviral therapy of HIV-infected infants in resource-limited countries: possible, feasible, effective and challenging. <i>Aids</i> , 2008, 22, 1365-1368.	2.2	7
270	Programmatic Impact of the Evolution of WHO Pediatric Antiretroviral Treatment Guidelines for Resource-Limited Countries (Tukula Fenna Project, Uganda). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 522-525.	2.1	7

#	ARTICLE	IF	CITATIONS
271	Antibody Maturation and Viral Diversification in HIV-Infected Women. <i>PLoS ONE</i> , 2013, 8, e57350.	2.5	7
272	Eliminating Pediatric HIV-1 Infection. <i>New England Journal of Medicine</i> , 2016, 375, 192-194.	27.0	7
273	Using Observational Data to Inform HIV Policy Change for Children and Youth. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, S22-S26.	2.1	7
274	Association of Selected Phenotypic Markers of Lymphocyte Activation and Differentiation with Perinatal Human Immunodeficiency Virus Transmission and Infant Infection. <i>Vaccine Journal</i> , 2005, 12, 622-631.	3.1	6
275	Realization of an AIDS-Free Generation. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 339.	7.4	6
276	“There are no more secrets”: acceptability of a family-centered model of care for HIV positive children in Eswatini. <i>BMC Health Services Research</i> , 2020, 20, 951.	2.2	6
277	Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial. <i>PLoS ONE</i> , 2021, 16, e0246272.	2.5	6
278	Standardized Definitions of In Utero Human Immunodeficiency Virus and Antiretroviral Drug Exposure Among Children. <i>Clinical Infectious Diseases</i> , 2022, 75, 347-355.	5.8	6
279	Clinical and population-based study design considerations to accelerate the investigation of new antiretrovirals during pregnancy. <i>Journal of the International AIDS Society</i> , 2022, 25, .	3.0	6
280	Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission. <i>Aids</i> , 2006, 20, 637.	2.2	5
281	Stavudine Concentrations in Women Receiving Postpartum Antiretroviral Treatment and Their Breastfeeding Infants. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 462-465.	2.1	5
282	Maternal Highly Active Antiretroviral Therapy and Child HIV-Free Survival in Malawi, 2004–2009. <i>Maternal and Child Health Journal</i> , 2016, 20, 542-549.	1.5	5
283	Antiretroviral Therapy for Perinatal HIV Prevention. <i>New England Journal of Medicine</i> , 2017, 376, 699-700.	27.0	5
284	Outcomes of second-line antiretroviral therapy among children living with HIV: a global cohort analysis. <i>Journal of the International AIDS Society</i> , 2020, 23, e25477.	3.0	5
285	What babies need: accelerating access to current and novel antiretroviral drugs in neonates through pharmacokinetic studies. <i>Lancet HIV</i> , 2022, 9, e649-e657.	4.7	5
286	Perinatal Transmission of HIV in Women Receiving Zidovudine. <i>JAMA - Journal of the American Medical Association</i> , 1998, 280, 569.	7.4	4
287	Evaluation of Viral Load Thresholds for Predicting New World Health Organization Stage 3 and 4 Events in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 214-218.	2.1	4
288	Decision Making in a Time of Uncertainty: Dolutegravir for Reproductive-Age Women. <i>Annals of Internal Medicine</i> , 2019, 170, 658.	3.9	4

#	ARTICLE	IF	CITATIONS
289	SARS-COV-2 Maternal→Child Transmission. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, e263-e264.	2.0	4
290	The Role of Antiretroviral Therapy in the Management of HIV Infection in Women. <i>Clinical Obstetrics and Gynecology</i> , 1996, 39, 361-385.	1.1	4
291	RIFABUTIN. <i>Pediatric Infectious Disease Journal</i> , 1998, 17, 71-72.	2.0	4
292	Prophylactic Immune Globulin in Children with HIV Disease. <i>New England Journal of Medicine</i> , 1995, 332, 750-752.	27.0	3
293	Cotrimoxazole Prophylaxis in HIV→Infected Pregnant Women: Only a First Step. <i>Journal of Infectious Diseases</i> , 2006, 194, 1478-1480.	4.0	3
294	Total Lymphocyte Count: Not a Surrogate Marker for Risk of Death in HIV-Infected Ugandan Children. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 171-178.	2.1	3
295	Diagnosis of HIV Infection During Early Infancy: How Early Is Early Enough?. <i>Journal of Infectious Diseases</i> , 2016, 214, 1294-1296.	4.0	3
296	Bone Age and Mineral Density Assessments Using Plain Roentgenograms in Tenofovir-exposed Infants in Malawi and Brazil Enrolled in HIV Prevention Trials Network 057. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 184-188.	2.0	3
297	Brief Report: Pediatric Cancer Burden and Treatment Resources Within the Pediatric IeDEA Consortium. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 60-64.	2.1	3
298	A randomized controlled trial evaluating the effects of a family-centered HIV care model on viral suppression and retention in care of HIV-positive children in Eswatini. <i>PLoS ONE</i> , 2021, 16, e0256256.	2.5	3
299	Pregnancy and medicines: time for paradigm change. <i>Journal of the International AIDS Society</i> , 2022, 25, .	3.0	3
300	Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338). <i>AIDS Research and Therapy</i> , 2007, 4, 2.	1.7	2
301	Use of antiretrovirals in HIV-infected children in a tuberculosis prevention trial: IMPAACT P1041. <i>International Journal of Tuberculosis and Lung Disease</i> , 2017, 21, 38-45.	1.2	2
302	Preconception ART and preterm birth: real effect or selection bias? → Authors' reply. <i>Lancet HIV</i> , the, 2017, 4, e150-e151.	4.7	2
303	Characterising and managing paediatric SARSCoV→2 infection: Learning about the virus in a global classroom. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2021, 110, 409-422.	1.5	2
304	Early neurodevelopmental markers predictive of mortality in infants infected with HIV-1. <i>Developmental Medicine and Child Neurology</i> , 2003, 45, .	2.1	2
305	Prevention of Infections in Children with Human Immunodeficiency Virus Infection. <i>BioDrugs</i> , 1994, 1, 258-270.	0.7	1
306	Safety and effectiveness of efavirenz versus nevirapine-based regimens in resource-limited settings. <i>Aids</i> , 2012, 26, 639-641.	2.2	1

#	ARTICLE	IF	CITATIONS
307	Preventing Human Immunodeficiency Virus Acquisition in Youth Generations at Risk. JAMA Pediatrics, 2017, 171, 829.	6.2	1
308	Reply to Kojima and Klausner. Clinical Infectious Diseases, 2018, 67, 1469-1470.	5.8	1
309	A Framework for Coordination between Obstetric and Pediatric Providers in Public Health Emergencies: Lessons Learned from the Zika Outbreak in the United States, 2015 to 2017. American Journal of Perinatology, 2020, 37, 982-990.	1.4	1
310	Ethically designing research to inform multidimensional, rapidly evolving policy decisions: Lessons learned from the PROMISE HIV Perinatal Prevention Trial. Clinical Trials, 2021, 18, 174077452110457.	1.6	1
311	Population Pharmacokinetics of Dapsone in HIV-Infected Children. Pediatric Research, 1999, 45, 168A-168A.	2.3	1
312	The Need to Study Clinical Outcomes in Children and Adolescents With COVID-19 From Middle- and Low-Income Regions. JAMA Pediatrics, 2022, 176, 728.	6.2	1
313	Initiating and changing antiretroviral therapy. , 2005, , 355-376.		0
314	Initiating and changing antiretroviral therapy. , 0, , 415-438.		0
315	Prevention of Mother-to-Child Transmission of HIV-1. , 2008, , 497-512.		0
316	Routine Newborn HIV Testing: An Idea Whose Time Has Come: In Reply. Pediatrics, 2009, 123, e363-e364.	2.1	0
317	Postnatal Human Immunodeficiency Virus-1 Transmission After Cessation of Infant Extended Antiretroviral Prophylaxis and Effect of Maternal Highly Active Antiretroviral Therapy. Obstetrical and Gynecological Survey, 2010, 65, 150-151.	0.4	0
318	Three Postpartum Antiretroviral Regimens to Prevent Intrapartum HIV Infection. Obstetrical and Gynecological Survey, 2012, 67, 612-614.	0.4	0
319	Nevirapine prophylaxis during breastfeeding Authors' reply. Lancet, The, 2012, 379, 1788.	13.7	0
320	Prevention of mother-to-child transmission of HIV-1. , 2012, , 485-507.		0
321	Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. Obstetrical and Gynecological Survey, 2017, 72, 143-145.	0.4	0